Cost-effectiveness in Preventive Cardiology

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2004 Jun 24

PMID 15212723

Authors

William S Weintraub

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease remains a serious medical problem, which can be associated with death and disability on one hand, and considerable resource utilization on the other. The primary driver for choice of therapy must remain clinical efficacy. Once efficacy is established, cost-effectiveness analysis has an important role. Resources are limited, and responsible choices must be made. The methods involved in cost-effectiveness analysis are complicated and data for the analysis are generally not fully optimal. Nonetheless, cost-effectiveness analysis offers the best method for helping society make rational medical decisions. Effective interventions, when reasonably priced, for the prevention of cardiovascular disease have generally proven to be cost-effective.

References

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

Jones T, Eaton C . Cost-benefit analysis of walking to prevent coronary heart disease. Arch Fam Med. 1994; 3(8):703-10. DOI: 10.1001/archfami.3.8.703. View

Evans D . Principles involved in costing. Med J Aust. 1990; 153(S1):S10-2. DOI: 10.5694/j.1326-5377.1990.tb136982.x. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Loomes G, McKenzie L . The use of QALYs in health care decision making. Soc Sci Med. 1989; 28(4):299-308. DOI: 10.1016/0277-9536(89)90030-0. View

Hayward R, Manning W, Kaplan S, Wagner E, Greenfield S . Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997; 278(20):1663-9. View

. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA. 1996; 276(17):1409-15. View

Woolacott N, Jones L, Forbes C, Mather L, Sowden A, Song F . The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002; 6(16):1-245. DOI: 10.3310/hta6160. View

. State-specific prevalence among adults of current cigarette smoking and smokeless tobacco use and per capita tax-paid sales of cigarettes--United States, 1997. MMWR Morb Mortal Wkly Rep. 1998; 47(43):922-6. View

10.

Warner K . Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics. 1997; 11(6):538-49. DOI: 10.2165/00019053-199711060-00003. View

11.

Edelson J, Weinstein M, Tosteson A, Williams L, Lee T, Goldman L . Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990; 263(3):407-13. View

12.

Hsiao W, Braun P, Yntema D, BECKER E . Estimating physicians' work for a resource-based relative-value scale. N Engl J Med. 1988; 319(13):835-41. DOI: 10.1056/NEJM198809293191305. View

13.

Lamy A, Yusuf S, Pogue J, Gafni A . Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003; 107(7):960-5. DOI: 10.1161/01.cir.0000050600.49419.25. View

14.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

15.

Cook T, ORegan M, Galland R . Quality of life following percutaneous transluminal angioplasty for claudication. Eur J Vasc Endovasc Surg. 1996; 11(2):191-4. DOI: 10.1016/s1078-5884(96)80050-5. View

16.

Goldman L, Weinstein M, Goldman P, Williams L . Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991; 265(9):1145-51. View

17.

Tosteson A, Weinstein M, Hunink M, Mittleman M, Williams L, Goldman P . Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation. 1997; 95(1):24-30. DOI: 10.1161/01.cir.95.1.24. View

18.

Ashraf T, Hay J, Pitt B, Wittels E, Crouse J, Davidson M . Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996; 78(4):409-14. DOI: 10.1016/s0002-9149(96)00328-1. View

19.

Eastman R, Javitt J, Herman W, Dasbach E, Maier W, Dong F . Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997; 20(5):735-44. DOI: 10.2337/diacare.20.5.735. View

20.

DUSTAN H, Roccella E, Garrison H . Controlling hypertension. A research success story. Arch Intern Med. 1996; 156(17):1926-35. View